Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has received official notice from the Chinese Patent Office that it intends to grant a patent for reversing or inhibiting eye degeneration associated with dry eye syndrome, as well as certain surgical eye procedures, including Lasik and PRK, with thymosin beta analogues, and derivatives.
Subscribe to our email newsletter
The patent claims are based on a significant body of data supporting the use of thymosin beta 4 for wound healing of the cornea and other areas in and around the eye.
thymosin beta 4’s corneal wound healing properties are being tested in a RegeneRx-sponsored Phase II clinical trial in diabetic vitrectomy patients, where a portion of the outer layer of the cornea is sometimes removed in order for surgeons to perform the procedure.
Finkelstein, RegeneRx’s president and CEO, said: “We are very pleased to receive this patent notification. It not only addresses one of our current product development efforts, but also covers future business opportunities in one of the fastest growing health care markets in the world and with vast potential for other related pharmaceutical products. We look forward to the issuance of additional patents in the US and abroad in the coming months.”